Cargando…

Metabolic Reprogramming in Tumor Endothelial Cells

The dynamic crosstalk between the different components of the tumor microenvironment is critical to determine cancer progression, metastatic dissemination, tumor immunity, and therapeutic responses. Angiogenesis is critical for tumor growth, and abnormal blood vessels contribute to hypoxia and acido...

Descripción completa

Detalles Bibliográficos
Autores principales: García-Caballero, Melissa, Sokol, Liliana, Cuypers, Anne, Carmeliet, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9570383/
https://www.ncbi.nlm.nih.gov/pubmed/36232355
http://dx.doi.org/10.3390/ijms231911052
_version_ 1784810092690931712
author García-Caballero, Melissa
Sokol, Liliana
Cuypers, Anne
Carmeliet, Peter
author_facet García-Caballero, Melissa
Sokol, Liliana
Cuypers, Anne
Carmeliet, Peter
author_sort García-Caballero, Melissa
collection PubMed
description The dynamic crosstalk between the different components of the tumor microenvironment is critical to determine cancer progression, metastatic dissemination, tumor immunity, and therapeutic responses. Angiogenesis is critical for tumor growth, and abnormal blood vessels contribute to hypoxia and acidosis in the tumor microenvironment. In this hostile environment, cancer and stromal cells have the ability to alter their metabolism in order to support the high energetic demands and favor rapid tumor proliferation. Recent advances have shown that tumor endothelial cell metabolism is reprogrammed, and that targeting endothelial metabolic pathways impacts developmental and pathological vessel sprouting. Therefore, the use of metabolic antiangiogenic therapies to normalize the blood vasculature, in combination with immunotherapies, offers a clinical niche to treat cancer.
format Online
Article
Text
id pubmed-9570383
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-95703832022-10-17 Metabolic Reprogramming in Tumor Endothelial Cells García-Caballero, Melissa Sokol, Liliana Cuypers, Anne Carmeliet, Peter Int J Mol Sci Review The dynamic crosstalk between the different components of the tumor microenvironment is critical to determine cancer progression, metastatic dissemination, tumor immunity, and therapeutic responses. Angiogenesis is critical for tumor growth, and abnormal blood vessels contribute to hypoxia and acidosis in the tumor microenvironment. In this hostile environment, cancer and stromal cells have the ability to alter their metabolism in order to support the high energetic demands and favor rapid tumor proliferation. Recent advances have shown that tumor endothelial cell metabolism is reprogrammed, and that targeting endothelial metabolic pathways impacts developmental and pathological vessel sprouting. Therefore, the use of metabolic antiangiogenic therapies to normalize the blood vasculature, in combination with immunotherapies, offers a clinical niche to treat cancer. MDPI 2022-09-21 /pmc/articles/PMC9570383/ /pubmed/36232355 http://dx.doi.org/10.3390/ijms231911052 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
García-Caballero, Melissa
Sokol, Liliana
Cuypers, Anne
Carmeliet, Peter
Metabolic Reprogramming in Tumor Endothelial Cells
title Metabolic Reprogramming in Tumor Endothelial Cells
title_full Metabolic Reprogramming in Tumor Endothelial Cells
title_fullStr Metabolic Reprogramming in Tumor Endothelial Cells
title_full_unstemmed Metabolic Reprogramming in Tumor Endothelial Cells
title_short Metabolic Reprogramming in Tumor Endothelial Cells
title_sort metabolic reprogramming in tumor endothelial cells
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9570383/
https://www.ncbi.nlm.nih.gov/pubmed/36232355
http://dx.doi.org/10.3390/ijms231911052
work_keys_str_mv AT garciacaballeromelissa metabolicreprogrammingintumorendothelialcells
AT sokolliliana metabolicreprogrammingintumorendothelialcells
AT cuypersanne metabolicreprogrammingintumorendothelialcells
AT carmelietpeter metabolicreprogrammingintumorendothelialcells